Venture Challenge Alumnus SeraNovo Enters into a second License Agreement with Carna Biosciences for Development of Oral Formulation of Carna’s Kinase inhibitor
Leiden, May 18th, 2020: SeraNovo B.V. today announced that it has signed a second License Agreement with Carna Biosciences, Inc., a company engaged in the drug development of kinase inhibitors. Under the agreement, the companies will expand their existing collaboration and jointly develop an oral formulation of a new active ingredient with an enhanced bioavailability. Utilising its proprietary Deep Eutectic Solvent (DES) formulation platform, SeraNovo is formulating one of Carna’s proprietary drugs to increase its oral bioavailability. The DES formulation platform is based on GRAS excipients that are used for oral administration and broadly used in the industry. After our initial licence announcement in October 2019, SeraNovo is pleased to extend our relationship with Carna to include the formulation of another promising active ingredient. This expansion of our partnership with an industry leader is a great development towards wide spread adoption of our breakthrough formulation technology.